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Haemodilution with a Plasma Expander as




A gelatin plasma expander (Haemaccel) was used as a
priming fluid in 10 cases of mitral valve replacement.
Measurements of acid-base, coagulation, electrolytes,
platelets, urinary output and oxygenation were comparable
to those with other priming solutions.
S. Air. Med. J., 48, 1615 (1974).
Haemodilution has become accepted practice in the con-
duct of cardiopulmonary bypass in recent years, and 5%
dextrose in water or a balanced salt solution is commonly
used to prime cardiopulmonary bypass apparatus. Duri~g
bypass and in the immediate period thereafter the flUId
and electrolyte load is redistributed extravascularly and
excreted in the urine. This often necessitates frequent
'topping up' of the bypass apparatus, and the need. to
make decisions regarding the choice of 'top-up' fluids.
The use of blood in bypass procedures presents the prob-
lems of availability, considerable use of skilled time in
providing accurate matching, and in large amounts the
production of homologous blood syndrome.
Consequently we decided to investigate the place of a
plasma expander as a priming solution. There is so.me
evidence that dextrans have the ability to promote lffi-
proved flow in the microcirculation and thereby prevent
stagnation. However, they have the disadvantage of inter-
fering with coagulation mechanisms when used in lar~e
amounts. This could lead to difficulties in haemostasIs
after bypass in the heparinised patient. Haemaccel, a
modified gelatin, has been shown to be free of adverse
effects on coagulation mechanism. In a comparison with
dextrans, Eichler and Stephan I showed that factor V is
increased with Haemaccel, but reduced with dextrans,
whereas factors VIII and IX are unaffected by the gelatins,
but decreased with the dextrans.
The osmolarity of the agent is slightly greater than that
of blood, and for this reason it has been recommended
in the management of hypovolaemic shock. The limits of
haemodilution have not been precisely defined in man,
althou<>h there is a wealth of clinical experience which
indicat~s that haematocrits of between 20% and 30% are
Department of Anaesthetics, University of Natal, Durban
D. G. MOYES, M.B. CH.B., M.R.C.S., L.R.C.P., F.F.A.
P-rincipal Anaesthetist/Senior Lecturer
Date received: 1 May 1974.
13
best tolerated during cardiopulmonary bypass. Evidence
has shown that a progressive acidosis. develops during per-
fusion with very low haematocrits. '
Haemaccel has been investigated as a diluent for donor
blood. In a series of mock perfusions 50 0 dextrose/water
has been compared with Haemaccel and polyvinylpyrol-
lidine (periston-N; Bayer). Leutschaff' demonstrated that
the in vitro haemolysis was higher with dextrose and sug-
gested that the acidic pH of dextrose/water may have been
the cause. He demonstrated changes in the erythrocyte
diameter and volume during haemodilution, which was
more pronounced with glucose and with the presence of
acidic pH. Silvay et al.' demonstrated the effect of diluting
blood with Haemaccel, both in animals and in man, as a
diluent at cardiopulmonary bypass. Haemaccel, a modified
gelatin preparation, is slightly hypertonic and has an
osmolarity of 350 - 390 mmHg. The sodium, potassium and
calcium levels are 145, 5,1 and 12,5 mEq/litre, respective-
ly. Anions are provided in the form of chloride and poly-
peptide. The solution thus has a high calcium and high
chloride content. The pH is between 7,2 and 7,3 and the
solution has a relative viscosity (1,7) similar to that of
plasma.
PATIENTS AND METHODS
Ten adult patients selected for mitral valve replacement
were studied. They were selected at random and the
clinical status of each patient was comparable; they had
all received digitalis and diuretics as part of the presurgi-
cal preparation. The standard practice is to discontinue
digitalis 48 hours before surgery. The Temptrol oxygenator
used in these studies has a priming volume of 2,2 litres. In
this study the prime was made up of 1,5 litres of Haemac-
cel and 0,7 litres of Ringer's lactate. The premedication
used was papaveretum and hyoscine.
The anaesthetic sequence followed in this study was
thiopentone, muscle relaxant, nitrous oxide/ oxygen, and
controlled moderate hyperventilation. In addition, small
doses of droperidol and fentanyl were u~ d. The bypass
procedures were carried out at normothermia. The fol-
lowing parameters were monitored as a routine during the
procedure: radial artery pressure, central venous pressure,
ECG, nasopharyngeal temperature, urine volume, acid-
base status, coagulation studies, and serum electrolytes.
The last 4 measurements were taken after induction of
anaesthesia, before bypass, at half-hourly intervals on by-
pass, and hourly after bypass. The parameters were
measured finally at 24 hours.
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RESULTS
Coagulation: The prothrombin index, thrombotest, clot-
ting time, thrombin time, fibrin index, recalcification test,
fibrinolysis, and prothrombin consumption index were
measured regularly as described. Values obtained were
similar to those noted in association with bypass proce-
dures in which dextrose/water or Ringer's lactate was
used as priming solution. There was no clinical evidence
of deficient haemostasis, and no evidence of anaenUa in
the postoperative stage at 24 hours.
Urinary output: Pre-operatively the glomerular filtration
ratios varied from 35% to 88%, with a mean of 58%.
During cardiopulmonary bypass the lowest output was
2,5 rnl/kg/hour. In the postoperative phase output was
in general good, and with one exception exceeded 60 rnl/
hour. This patient required two incremental doses of
furosemide.
Electrolytes: Sodium, potassium, chloride and total
serum calcium were measured throughout this procedure.
Two patients required intravenous potassium after bypass
to counteract hypokalaemic dysrhythmia. The levels of
chloride and calcium remained within normal limits.
Platelets: In our experience with other priming solutions,
cardiopulmonary bypass depresses the platelet count to
about 50% of control values, recovering to about 67°(, at
24 hours. The platelet values in the patients receiving
Haemaccel followed this pattern.
Acid-base status: The use of Haemaccel tended to cause
a slight metabolic alkalosis, and sodium bicarbonate was
not required. The lowest base deficit recorded was -1,5
mEqjlitre.
Oxygenation: There was no difference in the arterial
oxygen level in this study compared with others in which
dextrose/water or Ringer's lactate were used as priming
media.
Blood loss: The mean recorded blood loss in the first
24 hours was 2,5 litres. Haematocrits returned to pre-by-
pass levels 2 - 3 hours after bypass in every patient. In a
large series of mitral valve replacements with other priming
media the mean loss was 2,9 litres.
DISCUSSION
Haemaccel can be recommended theoretically as a priming
fluid at cardiopulmonary bypass by virtue of its pH,
flow characteristics, absence of effect on coagulation
mechanisms, absence of antigenic propensities, and stabi-
lity in storage. The molecular size of Haemaccel ranges
from 5 000 to 50 000, with a mean molecular weight of
between 30000 and 35000 and a half-life of between 8
and 10 hours.
Extensive clinical experience has indicated that haemo-
dilution to a haematocrit of 20 - 30°(, produces the best
results in terms of tissue respiration and electrolyte and
coagulation haemostasis. It is desirable that the diluent
chosen will not challenge these ends. For ease of manage-
ment, it is desirable that the diluent will stay within the
vascular space for the duration of cardiopulmonary by-
pass, and that renal elimination should occur to restore
the haematocrit to within 10% of normal in the immediate
postoperative period. Haemaccel appeared in this short
study to fulfil the criteria outlined above, and merits
further intensive clinical trial.
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